PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT

PACE-NODES is a phase III randomised controlled trial for patients with high risk localised prostate cancer, planned for radical radiotherapy with at least 12 months of androgen deprivation therapy, and suitable for stereotactic body radiotherapy (SBRT). Patients are randomised to receive either prostate SBRT (control) or prostate and pelvic nodal SBRT. In both arms, treatment is given in 5 fractions delivered on alternate days over 2 weeks. The aim of the trial is to determine whether prostate and pelvic nodal SBRT can improve outcomes for this patient group compared to prostate SBRT. <b>Clinical trial registration:</b> PACE NODES is registered on ClinicalTrials.gov (NCT05613023).

Authors

Institutions

Publication Details

Journal
Clinical and Translational Radiation Oncology
Published
2026-02-12
DOI
https://doi.org/10.1016/j.ctro.2026.101126
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT

Tim Ward, Monisha Dewan, Fay Cafferty, Olivia Naismith et al.
Clinical and Translational Radiation Oncology
Prostate Cancer Diagnosis and Treatment
article

PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT

Tim Ward, Monisha Dewan, Fay Cafferty, Olivia Naismith, Elizabeth Miles, Ken McBride, Emma Hall, Yee Pei Song, Stephanie Brown, Conor K McGarry, Alison Tree, Peter Hoskin, Ananya Choudhury, Nicholas van As, John Staffurth, Julia Murray, Suneil Jain, Vedang Murthy, Isabel Syndikus, Stephanie Burnett, Angela Pathmanathan
article en

Abstract

PACE-NODES is a phase III randomised controlled trial for patients with high risk localised prostate cancer, planned for radical radiotherapy with at least 12 months of androgen deprivation therapy, and suitable for stereotactic body radiotherapy (SBRT). Patients are randomised to receive either prostate SBRT (control) or prostate and pelvic nodal SBRT. In both arms, treatment is given in 5 fractions delivered on alternate days over 2 weeks. The aim of the trial is to determine whether prostate and pelvic nodal SBRT can improve outcomes for this patient group compared to prostate SBRT. <b>Clinical trial registration:</b> PACE NODES is registered on ClinicalTrials.gov (NCT05613023).

Clinical and Translational Radiation OncologyVol. 58
UK Health Forum (GB), Queen's University Belfast (GB), Belfast Health and Social Care Trust (GB), Royal Marsden NHS Foundation Trust (GB), Institute of Cancer Research (GB), Velindre NHS Trust (GB), Tata Memorial Hospital (IN), Mount Vernon Hospital (GB), Clatterbridge Cancer Centre NHS Foundation Trust (GB), University of Manchester (GB), The Christie NHS Foundation Trust (GB), Mount Vernon Hospital (GB), Cardiff University (GB)
Pancreatic Cancer UK, Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, Prostate Cancer UK, Auckland Medical Research Foundation, Irish Cancer Society
Good health and well-being
Openalex Percentile: Top 61%
Prostate Cancer Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.